^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Biliary Tract Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma
Excerpt:
...Determine the ORR of subgroups stratified by molecular signatures (tumor mutation burden, PD-L1 expression, MSI status, FGFR mutation/fusion status) in a pre-planned post-hoc analysis`Determine the PFS of subgroups stratified by molecular signatures (tumor mutation burden, PD-L1 expression, MSI status, FGFR mutation/fusion status) in a pre-planned post-hoc analysis`Determine the OS of subgroups stratified by molecular signatures (tumor mutation burden, PD-L1 expression, MSI status, FGFR mutation/fusion status) in a pre-planned post-hoc analysis...
Source:
Title:
Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study.
Published date:
05/19/2021
Excerpt:
...eligible patients were aged ≥18 years with histologically or cytologically documented advanced (metastatic and/or unresectable) BTC with disease progression after 1 prior line of therapy...ECOG PS of 0‒1, and tissue sample evaluable for PD-L1 expression...ORR was 10% (95% CI, 2‒26), and DCR was 68%...Median PFS was 6.1 months...Median OS was 8.6 months....Lenvatinib plus pembrolizumab demonstrated encouraging efficacy and manageable toxicity in patients with advanced BTC...
DOI:
10.1200/JCO.2021.39.15_suppl.4080
Trial ID:
